734
Views
4
CrossRef citations to date
0
Altmetric
Review Articles

Interplay between gut microbiota and bile acids in diarrhoea-predominant irritable bowel syndrome: a review

ORCID Icon, , &
Pages 696-713 | Received 24 May 2021, Accepted 03 Nov 2021, Published online: 22 Dec 2021

References

  • Abt MC, McKenney PT, Pamer EG. 2016. Clostridium difficile colitis: pathogenesis and host defence. Nat Rev Microbiol. 14(10):609–620.
  • Agrawal A, Houghton LA, Morris J, Reilly B, Guyonnet D, Goupil Feuillerat N, Schlumberger A, Jakob S, Whorwell PJ. 2009. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 29(1):104–114.
  • Alemán JO, Bokulich NA, Swann JR, Walker JM, De Rosa JC, Battaglia T, Costabile A, Pechlivanis A, Liang Y, Breslow JL, et al. 2018. Fecal microbiota and bile acid interactions with systemic and adipose tissue metabolism in diet-induced weight loss of obese postmenopausal women. J Transl Med. 16(1):244.
  • Aroniadis OC, Brandt LJ, Oneto C, Feuerstadt P, Sherman A, Wolkoff AW, Kassam Z, Sadovsky RG, Elliott RJ, Budree S, et al. 2019. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 4(9):675–685.
  • Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto J-M, et al. 2011. Enterotypes of the human gut microbiome. Nature. 473(7346):174–180.
  • Aziz I, Mumtaz S, Bholah H, Chowdhury FU, Sanders DS, Ford AC. 2015. High prevalence of idiopathic bile acid diarrhea among patients with diarrhea-predominant irritable bowel syndrome based on Rome III criteria. Clin Gastroenterol Hepatol. 13(9):1650–1655.e2.
  • Bajor A, Kilander A, Fae A, Gälman C, Jonsson O, Ohman L, et al. 2006. Normal or increased bile acid uptake in isolated mucosa from patients with bile acid malabsorption. Eur J Gastroenterol Hepatol. 18(4):397–403.
  • Bajor A, Törnblom H, Rudling M, Ung KA, Simrén M. 2015. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut. 64(1):84–92.
  • Barkun AN, Love J, Gould M, Pluta H, Steinhart H. 2013. Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment. Can J Gastroenterol. 27(11):653–659.
  • Begley M, Gahan CG, Hill C. 2005. The interaction between bacteria and bile. FEMS Microbiol Rev. 29(4):625–651.
  • Beli E, Yan Y, Moldovan L, Vieira CP, Gao R, Duan Y, Prasad R, Bhatwadekar A, White FA, Townsend SD, et al. 2018. Restructuring of the gut microbiome by intermittent fasting prevents retinopathy and prolongs survival in db/db mice. Diabetes. 67(9):1867–1879.
  • Black CJ, Ford AC. 2020. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 17(8):473–486.
  • Borup C, Wildt S, Rumessen J, Graff J, Bouchelouche PN, Andersen TB, Vinter-Jensen L, Zaremba A, German Jørgensen SP, Gregersen T, et al. 2020. Biochemical diagnosis of bile acid diarrhea: prospective comparison with the 75seleno-taurohomocholic acid test. Am J Gastroenterol. 115(12):2086–2094.
  • Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon J-P, van Deventer SJH, Neirynck S, Peppelenbosch MP, Steidler L, et al. 2006. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol. 4(6):754–759.
  • Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, et al. 2015. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 517(7533):205–208.
  • Camilleri M, Acosta A, Busciglio I, Boldingh A, Dyer RB, Zinsmeister AR, Lueke A, Gray A, Donato LJ. 2015. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 41(5):438–448.
  • Camilleri M, Busciglio I, Acosta A, Shin A, Carlson P, Burton D, Ryks M, Rhoten D, Lamsam J, Lueke A, et al. 2014. Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea. Am J Gastroenterol. 109(10):1621–1630.
  • Camilleri M, Carlson P, Acosta A, Busciglio I. 2015. Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion. Am J Physiol Gastrointest Liver Physiol. 309(1):G10–G20.
  • Camilleri M, Shin A, Busciglio I, Carlson P, Acosta A, Bharucha AE, Burton D, Lamsam J, Lueke A, Donato LJ, et al. 2014. Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion. Am J Physiol Gastrointest Liver Physiol. 307(5):G508–G516.
  • Camilleri M, Vijayvargiya P. 2020. The role of bile acids in chronic diarrhea. Am J Gastroenterol. 115(10):1596–1603.
  • Camilleri M. 2013. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. 368(6):578–579.
  • Camilleri M. 2014. Advances in understanding of bile acid diarrhea. Expert Rev Gastroenterol Hepatol. 8(1):49–61.
  • Camilleri M. 2015. Bile Acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver. 9(3):332–339.
  • Cao H, Xu M, Dong W, Deng B, Wang S, Zhang Y, Wang S, Luo S, Wang W, Qi Y, et al. 2017. Secondary bile acid-induced dysbiosis promotes intestinal carcinogenesis. Int J Cancer. 140(11):2545–2556.
  • Carco C, Young W, Gearry RB, Talley NJ, McNabb WC, Roy NC. 2020. Increasing evidence that irritable bowel syndrome and functional gastrointestinal disorders have a microbial pathogenesis. Front Cell Infect Microbiol. 10:468.
  • Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y. 2012. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 24(6):521–530.
  • Chiang JYL, Ferrell JM. 2020. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am J Physiol Gastrointest Liver Physiol. 318(3):G554–G573.
  • Chow MD, Lee YH, Guo GL. 2017. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol Aspects Med. 56:34–44.
  • Cipriani S, Mencarelli A, Chini MG, Distrutti E, Renga B, Bifulco G, Baldelli F, Donini A, Fiorucci S. 2011. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLOS One. 6(10):e25637.
  • Daniel H. 2020. Diet and the gut microbiome: from hype to hypothesis. Br J Nutr. 124(6):521–530.
  • David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, et al. 2014. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 505(7484):559–563.
  • De Palma G, Lynch MD, Lu J, Dang VT, Deng Y, Jury J, et al. 2017. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci Transl Med. 9(379):eaaf6397.
  • Degirolamo C, Rainaldi S, Bovenga F, Murzilli S, Moschetta A. 2014. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep. 7(1):12–18.
  • Devkota S, Chang EB. 2015. Interactions between diet, bile acid metabolism, gut microbiota, and inflammatory bowel diseases. Dig Dis. 33(3):351–356.
  • Devlin AS, Fischbach MA. 2015. A biosynthetic pathway for a prominent class of microbiota-derived bile acids. Nat Chem Biol. 11(9):685–690.
  • Dey N, Wagner VE, Blanton LV, Cheng J, Fontana L, Haque R, Ahmed T, Gordon JI. 2015. Regulators of gut motility revealed by a gnotobiotic model of diet-microbiome interactions related to travel. Cell. 163(1):95–107.
  • Dickinson AB, Gustafsson BE, Norman A. 1971. Determination of bile acid conversion potencies of intestinal bacteria by screening in vitro and subsequent establishment in germfree rats. Acta Pathol Microbiol Scand B Microbiol Immunol. 79(5):691–698.
  • Dior M, Delagrèverie H, Duboc H, Jouet P, Coffin B, Brot L, Humbert L, Trugnan G, Seksik P, Sokol H, et al. 2016. Interplay between bile acid metabolism and microbiota in irritable bowel syndrome. Neurogastroenterol Motil. 28(9):1330–1340.
  • Dobbins JW, Binder HJ. 1976. Effect of bile salts and fatty acids on the colonic absorption of oxalate. Gastroenterology. 70(6):1096–1100.
  • Duboc H, Rainteau D, Rajca S, Humbert L, Farabos D, Maubert M, Grondin V, Jouet P, Bouhassira D, Seksik P, et al. 2012. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 24(6):513–520.
  • Ducarmon QR, Zwittink RD, Hornung BVH, van Schaik W, Young VB, Kuijper EJ. 2019. Gut microbiota and colonization resistance against bacterial enteric infection. Microbiol Mol Biol Rev. 83(3):e00007-19.
  • Durbán A, Abellán JJ, Jiménez-Hernández N, Artacho A, Garrigues V, Ortiz V, Ponce J, Latorre A, Moya A. 2013. Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome. FEMS Microbiol Ecol. 86(3):581–589.
  • Edenharder R, Schneider J. 1985. 12 beta-dehydrogenation of bile acids by Clostridium paraputrificum, C. tertium, and C. difficile and epimerization at carbon-12 of deoxycholic acid by cocultivation with 12 alpha-dehydrogenating Eubacterium lentum. Appl Environ Microbiol. 49(4):964–968.
  • Edogawa S, Edwinson AL, Peters SA, Chikkamenahalli LL, Sundt W, Graves S, Gurunathan SV, Breen-Lyles M, Johnson S, Dyer R, et al. 2020. Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS. Gut. 69(1):62–73.
  • El-Salhy M, Hatlebakk JG, Gilja OH, Bråthen Kristoffersen A, Hausken T. 2020. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 69(5):859–867.
  • El-Salhy M, Hausken T, Hatlebakk JG. 2019. Increasing the dose and/or repeating faecal microbiota transplantation (FMT) increases the response in patients with irritable bowel syndrome (IBS). Nutrients. 11(6):1415.
  • Ferrari A, Pacini N, Canzi E. 1980. A note on bile acids transformations by strains of Bifidobacterium. J Appl Bacteriol. 49(2):193–197.
  • Fiorucci S, Distrutti E. 2015. Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders. Trends Mol Med. 21(11):702–714.
  • Flacco ME, Manzoli L, De Giorgio R, Gasbarrini A, Cicchetti A, Bravi F, Altini M, Caio GP, Ursini F. 2019. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur Rev Med Pharmacol Sci. 23(7):2986–3000.
  • Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. 2018. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 48(10):1044–1060.
  • Ford AC, Sperber AD, Corsetti M, Camilleri M. 2020. Irritable bowel syndrome. Lancet. 396(10263):1675–1688.
  • Fu T, Coulter S, Yoshihara E, Oh TG, Fang S, Cayabyab F, Zhu Q, Zhang T, Leblanc M, Liu S, et al. 2019. FXR regulates intestinal cancer stem cell proliferation. Cell. 176(5):1098–1112.e18.
  • Fujisaka S, Ussar S, Clish C, Devkota S, Dreyfuss JM, Sakaguchi M, Soto M, Konishi M, Softic S, Altindis E, et al. 2016. Antibiotic effects on gut microbiota and metabolism are host dependent. J Clin Invest. 126(12):4430–4443.
  • Gagliardi A, Totino V, Cacciotti F, Iebba V, Neroni B, Bonfiglio G, et al. 2018. Rebuilding the gut microbiota ecosystem. Int J Environ Res Public Health. 15(8):1679.
  • Ghoshal UC, Gwee KA. 2017. Post-infectious IBS, tropical sprue and small intestinal bacterial overgrowth: the missing link. Nat Rev Gastroenterol Hepatol. 14(7):435–441.
  • Gu X, Song LJ, Li LX, Liu T, Zhang MM, Li Z, et al. 2020. Fusobacterium nucleatum causes microbial dysbiosis and exacerbates visceral hypersensitivity in a colonization-independent manner. Front Microbiol. 11:1281.
  • Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier C-H, Matuchansky C. 2007. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther. 26(3):475–486.
  • Hirano S, Masuda N, Oda H, Mukai H. 1981. Transformation of bile acids by Clostridium perfringens. Appl Environ Microbiol. 42(3):394–399.
  • Hirano S, Masuda N. 1981. Transformation of bile acids by Eubacterium lentum. Appl Environ Microbiol. 42(5):912–915.
  • Hirano S, Masuda N. 1982. Characterization of NADP-dependent 7 beta-hydroxysteroid dehydrogenases from Peptostreptococcus productus and Eubacterium aerofaciens. Appl Environ Microbiol. 43(5):1057–1063.
  • Hylemon PB, Sherrod JA. 1975. Multiple forms of 7-alpha-hydroxysteroid dehydrogenase in selected strains of Bacteroides fragilis. J Bacteriol. 122(2):418–424.
  • Inagaki T, Moschetta A, Lee Y-K, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, et al. 2006. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA. 103(10):3920–3925.
  • Ipharraguerre IR, Pastor JJ, Gavaldà-Navarro A, Villarroya F, Mereu A. 2018. Antimicrobial promotion of pig growth is associated with tissue-specific remodeling of bile acid signature and signaling. Sci Rep. 8(1):13671.
  • Islam KBMS, Fukiya S, Hagio M, Fujii N, Ishizuka S, Ooka T, Ogura Y, Hayashi T, Yokota A. 2011. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology. 141(5):1773–1781.
  • Jalanka-Tuovinen J, Salojärvi J, Salonen A, Immonen O, Garsed K, Kelly FM, Zaitoun A, Palva A, Spiller RC, de Vos WM, et al. 2014. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 63(11):1737–1745.
  • Jeffery IB, Das A, O'Herlihy E, Coughlan S, Cisek K, Moore M, Bradley F, Carty T, Pradhan M, Dwibedi C, et al. 2020. Differences in fecal microbiomes and metabolomes of people with vs without irritable bowel syndrome and bile acid malabsorption. Gastroenterology. 158(4):1016–1028.e8.
  • Jeffery IB, O'Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EMM, Simrén M. 2012. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 61(7):997–1006.
  • Jena PK, Sheng L, Li Y, Wan YY. 2020. Probiotics VSL#3 are effective in reversing non-alcoholic steatohepatitis in a mouse model. Hepatobiliary Surg Nutr. 9(2):170–182.
  • Jia B, Park D, Hahn Y, Jeon CO. 2020. Metagenomic analysis of the human microbiome reveals the association between the abundance of gut bile salt hydrolases and host health. Gut Microbes. 11(5):1300–1313.
  • Jia W, Xie G, Jia W. 2018. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 15(2):111–128.
  • Johnsen PH, Hilpüsch F, Valle PC, Goll R. 2020. The effect of fecal microbiota transplantation on IBS related quality of life and fatigue in moderate to severe non-constipated irritable bowel: secondary endpoints of a double blind, randomized, placebo-controlled trial. EBioMedicine. 51:102562.
  • Jones BV, Begley M, Hill C, Gahan CG, Marchesi JR. 2008. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci USA. 105(36):13580–13585.
  • Joyce SA, Gahan CG. 2017. Disease-associated changes in bile acid profiles and links to altered gut microbiota. Dig Dis. 35(3):169–177.
  • Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, et al. 2003. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 278(11):9435–9440.
  • Kim NH, Park JH, Park JS, Joung YH. 2017. The effect of deoxycholic acid on secretion and motility in the rat and guinea pig large intestine. J Neurogastroenterol Motil. 23(4):606–615.
  • Kirwan WO, Smith AN, Mitchell WD, Falconer JD, Eastwood MA. 1975. Bile acids and colonic motility in the rabbit and the human. Gut. 16(11):894–902.
  • Klindt C, Reich M, Hellwig B, Stindt J, Rahnenführer J, Hengstler JG, Köhrer K, Schoonjans K, Häussinger D, Keitel V, et al. 2019. The G protein-coupled bile acid receptor TGR5 (Gpbar1) modulates endothelin-1 signaling in liver. Cells. 8(11):1467.
  • Kriaa A, Bourgin M, Potiron A, Mkaouar H, Jablaoui A, Gérard P, Maguin E, Rhimi M. 2019. Microbial impact on cholesterol and bile acid metabolism: current status and future prospects. J Lipid Res. 60(2):323–332.
  • Kurdi P, Kawanishi K, Mizutani K, Yokota A. 2006. Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria. J Bacteriol. 188(5):1979–1986.
  • Labus JS, Hollister EB, Jacobs J, Kirbach K, Oezguen N, Gupta A, Acosta J, Luna RA, Aagaard K, Versalovic J, et al. 2017. Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome. Microbiome. 5(1):49.
  • Li T, Chiang JY. 2014. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev. 66(4):948–983.
  • Li W-T, Luo Q-Q, Wang B, Chen X, Yan X-J, Qiu H-Y, Chen S-L. 2019. Bile acids induce visceral hypersensitivity via mucosal mast cell-to-nociceptor signaling that involves the farnesoid X receptor/nerve growth factor/transient receptor potential vanilloid 1 axis. FASEB J. 33(2):2435–2450.
  • Lin H, An Y, Tang H, Wang Y. 2019. Alterations of bile acids and gut microbiota in obesity induced by high fat diet in rat model. J Agric Food Chem. 67(13):3624–3632.
  • Liu HN, Wu H, Chen YZ, Chen YJ, Shen XZ, Liu TT. 2017. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: a systematic review and meta-analysis. Dig Liver Dis. 49(4):331–337.
  • Long SL, Gahan CGM, Joyce SA. 2017. Interactions between gut bacteria and bile in health and disease. Mol Aspects Med. 56:54–65.
  • Lorenzo-Zúñiga V, Bartolí R, Planas R, Hofmann AF, Viñado B, Hagey LR, et al. 2003. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology. 37(3):551–557.
  • Luo L, Liu Y, Cai X, Wang Y, Xue J, Zhang J, Yang F. 2019. Bletilla striata polysaccharides ameliorates lipopolysaccharide-induced injury in intestinal epithelial cells. Saudi J Gastroenterol. 25(5):302–308.
  • Marteau P, Cuillerier E, Meance S, Gerhardt MF, Myara A, Bouvier M, Bouley C, Tondu F, Bommelaer G, Grimaud JC, et al. 2002. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther. 16(3):587–593.
  • Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M. 2016. Bowel disorders. Gastroenterology. S0016-5085(16)00222-5.
  • Meng C, Bai C, Brown TD, Hood LE, Tian Q. 2018. Human gut microbiota and gastrointestinal cancer. Genomics Proteomics Bioinformatics. 16(1):33–49.
  • Molinaro A, Wahlström A, Marschall HU. 2018. Role of bile acids in metabolic control. Trends Endocrinol Metab. 29(1):31–41.
  • Montagnani M, Abrahamsson A, Gälman C, Eggertsen G, Marschall H-U, Ravaioli E, Einarsson C, Dawson PA. 2006. Analysis of ileal sodium/bile acid cotransporter and related nuclear receptor genes in a family with multiple cases of idiopathic bile acid malabsorption. World J Gastroenterol. 12(47):7710–7714.
  • Mottacki N, Simrén M, Bajor A. 2016. Review article: bile acid diarrhoea – pathogenesis, diagnosis and management. Aliment Pharmacol Ther. 43(8):884–898.
  • Odunsi–Shiyanbade ST, Camilleri M, McKinzie S, Burton D, Carlson P, Busciglio IA, Lamsam J, Singh R, Zinsmeister AR. 2010. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol. 8(2):159–165.
  • Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. 2020. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 5(10):908–917.
  • Paramsothy S, Nielsen S, Kamm MA, Deshpande NP, Faith JJ, Clemente JC, Paramsothy R, Walsh AJ, van den Bogaerde J, Samuel D, et al. 2019. Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis. Gastroenterology. 156(5):1440–1454.e2.
  • Parséus A, Sommer N, Sommer F, Caesar R, Molinaro A, Ståhlman M, Greiner TU, Perkins R, Bäckhed F. 2017. Microbiota-induced obesity requires farnesoid X receptor. Gut. 66(3):429–437.
  • Pathak P, Xie C, Nichols RG, Ferrell JM, Boehme S, Krausz KW, Patterson AD, Gonzalez FJ, Chiang JYL. 2018. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology. 68(4):1574–1588.
  • Peleman C, Camilleri M, Busciglio I, Burton D, Donato L, Zinsmeister AR. 2017. Colonic transit and bile acid synthesis or excretion in patients with irritable bowel syndrome-diarrhea without bile acid malabsorption. Clin Gastroenterol Hepatol. 15(5):720–727.e1.
  • Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, Moayyedi P. 2019. Gut microbiota in patients with irritable bowel syndrome–a systematic review. Gastroenterology. 157(1):97–108.
  • Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, et al. 2010. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 464(7285):59–65.
  • Rajilić-Stojanović M, de Vos WM. 2014. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev. 38(5):996–1047.
  • Rao AS, Wong BS, Camilleri M, Odunsi-Shiyanbade ST, McKinzie S, Ryks M, Burton D, Carlson P, Lamsam J, Singh R, et al. 2010. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology. 139(5):1549–1558.e1.
  • Ridlon JM, Alves JM, Hylemon PB, Bajaj JS. 2013. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes. 4(5):382–387.
  • Ridlon JM, Bajaj JS. 2015. The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics. Acta Pharm Sin B. 5(2):99–105.
  • Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB. 2016. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes. 7(1):22–39.
  • Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. 2014. Bile acids and the gut microbiome. Curr Opin Gastroenterol. 30(3):332–338.
  • Ridlon JM, Kang DJ, Hylemon PB. 2006. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 47(2):241–259.
  • Robben J, Janssen G, Merckx R, Eyssen H. 1989. Formation of delta 2- and delta 3-cholenoic acids from bile acid 3-sulfates by a human intestinal Fusobacterium strain. Appl Environ Microbiol. 55(11):2954–2959.
  • Robben J, Parmentier G, Eyssen H. 1986. Isolation of a rat intestinal Clostridium strain producing 5 alpha- and 5 beta-bile salt 3 alpha-sulfatase activity. Appl Environ Microbiol. 51(1):32–38.
  • Rodiño-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-García R, Santos J. 2018. A review of microbiota and irritable bowel syndrome: future in therapies. Adv Ther. 35(3):289–310.
  • Round JL, Mazmanian SK. 2010. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA. 107(27):12204–12209.
  • Sadik R, Abrahamsson H, Ung KA, Stotzer PO. 2004. Accelerated regional bowel transit and overweight shown in idiopathic bile acid malabsorption. Am J Gastroenterol. 99(4):711–718.
  • Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall H-U, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F, et al. 2013. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17(2):225–235.
  • Shin A, Camilleri M, Vijayvargiya P, Busciglio I, Burton D, Ryks M, Rhoten D, Lueke A, Saenger A, Girtman A, et al. 2013. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 11(10):1270–1275.e1.
  • Song Z, Cai Y, Lao X, Wang X, Lin X, Cui Y, Kalavagunta PK, Liao J, Jin L, Shang J, et al. 2019. Taxonomic profiling and populational patterns of bacterial bile salt hydrolase (BSH) genes based on worldwide human gut microbiome. Microbiome. 7(1):9.
  • Spencer NJ, Hu H. 2020. Enteric nervous system: sensory transduction, neural circuits and gastrointestinal motility. Nat Rev Gastroenterol Hepatol. 17(6):338–351.
  • Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, Whitehead WE, Dumitrascu DL, Fang X, Fukudo S, et al. 2020. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 160(1):99–114.e3.
  • Staley C, Weingarden AR, Khoruts A, Sadowsky MJ. 2017. Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Appl Microbiol Biotechnol. 101(1):47–64.
  • Stotzer PO, Abrahamsson H, Bajor A, Sadik R. 2013. Effect of cholestyramine on gastrointestinal transit in patients with idiopathic bile acid diarrhea: a prospective, open-label study. Neuroenterology. 2(9):1–5.
  • Sun L, Pang Y, Wang X, Wu Q, Liu H, Liu B, Liu G, Ye M, Kong W, Jiang C, et al. 2019. Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters. Acta Pharm Sin B. 9(4):702–710.
  • Sun W, Guo Y, Zhang S, Chen Z, Wu K, Liu Q, Liu K, Wen L, Wei Y, Wang B, et al. 2018. Fecal microbiota transplantation can alleviate gastrointestinal transit in rats with high-fat diet-induced obesity via regulation of serotonin biosynthesis. Biomed Res Int. 2018:8308671.
  • Sundin J, Rangel I, Fuentes S, Heikamp-de Jong I, Hultgren-Hörnquist E, de Vos WM, Brummer RJ. 2015. Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment Pharmacol Ther. 41(4):342–351.
  • Tap J, Derrien M, Törnblom H, Brazeilles R, Cools-Portier S, Doré J, Störsrud S, Le Nevé B, Öhman L, Simrén M, et al. 2017. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 152(1):111–123.e8.
  • Theriot CM, Koenigsknecht MJ, Carlson PE, Hatton GE, Nelson AM, Li B, Huffnagle GB, Z Li J, Young VB. 2014. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun. 5:3114.
  • Ticho AL, Malhotra P, Dudeja PK, Gill RK, Alrefai WA. 2019. Intestinal absorption of bile acids in health and disease. Compr Physiol. 10(1):21–56.
  • Torres-Fuentes C, Schellekens H, Dinan TG, Cryan JF. 2017. The microbiota-gut-brain axis in obesity. Lancet Gastroenterol Hepatol. 2(10):747–756.
  • Traub RJ, Tang B, Ji Y, Pandya S, Yfantis H, Sun Y. 2008. A rat model of chronic postinflammatory visceral pain induced by deoxycholic acid. Gastroenterology. 135(6):2075–2083.
  • Valeur J, Småstuen MC, Knudsen T, Lied GA, Røseth AG. 2018. Exploring gut microbiota composition as an indicator of clinical response to dietary FODMAP restriction in patients with irritable bowel syndrome. Dig Dis Sci. 63(2):429–436.
  • Van Eldere J, Mertens J, Eyssen H. 1990. Influence of intestinal bacterial desulfation on the enterohepatic circulation of dehydroepiandrosterone sulfate. J Steroid Biochem. 36(5):451–456.
  • Van Eldere J, Robben J, De Pauw G, Merckx R, Eyssen H. 1988. Isolation and identification of intestinal steroid-desulfating bacteria from rats and humans. Appl Environ Microbiol. 54(8):2112–2117.
  • Vich Vila A, Imhann F, Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, et al. 2018. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci Transl Med. 10(472):eaap8914.
  • Vijayvargiya P, Camilleri M, Chedid V, Carlson P, Busciglio I, Burton D, Donato LJ. 2019. Analysis of fecal primary bile acids detects increased stool weight and colonic transit in patients with chronic functional diarrhea. Clin Gastroenterol Hepatol. 17(5):922–929.e2.
  • Wahlström A, Kovatcheva-Datchary P, Ståhlman M, Khan MT, Bäckhed F, Marschall HU. 2017. Induction of farnesoid X receptor signaling in germ-free mice colonized with a human microbiota. J Lipid Res. 58(2):412–419.
  • Wahlström A, Sayin SI, Marschall HU, Bäckhed F. 2016. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24(1):41–50.
  • Wang L, Alammar N, Singh R, Nanavati J, Song Y, Chaudhary R, Mullin GE. 2020. Gut microbial dysbiosis in the irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. J Acad Nutr Diet. 120(4):565–586.
  • Wang S, Dong W, Liu L, Xu M, Wang Y, Liu T, Zhang Y, Wang B, Cao H. 2019. Interplay between bile acids and the gut microbiota promotes intestinal carcinogenesis. Mol Carcinog. 58(7):1155–1167.
  • Wang Z, Zhao Y. 2018. Gut microbiota derived metabolites in cardiovascular health and disease. Protein Cell. 9(5):416–431.
  • Watanabe M, Fukiya S, Yokota A. 2017. Comprehensive evaluation of the bactericidal activities of free bile acids in the large intestine of humans and rodents. J Lipid Res. 58(6):1143–1152.
  • Wei W, Wang HF, Zhang Y, Zhang YL, Niu BY, Yao SK. 2020. Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome. WJG. 26(45):7153–7172.
  • Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, Sadowsky MJ, Khoruts A. 2014. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol. 306(4):G310–G319.
  • Weingarden AR, Dosa PI, DeWinter E, Steer CJ, Shaughnessy MK, Johnson JR, Khoruts A, Sadowsky MJ. 2016. Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control Clostridium difficile germination and growth. PLOS One. 11(1):e0147210.
  • Wingate DL, Krag E, Mekhjian HS, Phillips SF. 1973. Relationships between ion and water movement in the human jejunum, ileum and colon during perfusion with bile acids. Clin Sci Mol Med. 45(5):593–606.
  • Winston JA, Theriot CM. 2020. Diversification of host bile acids by members of the gut microbiota. Gut Microbes. 11(2):158–171.
  • Wong BS, Camilleri M, Carlson PJ, Odunsi-Shiyanbade S, McKinzie S, Busciglio I, Burton D, Zinsmeister AR. 2012. Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea. Dig Dis Sci. 57(5):1222–1226.
  • Wu KQ, Sun WJ, Li N, Chen YQ, Wei YL, Chen DF. 2019. Small intestinal bacterial overgrowth is associated with diarrhea-predominant irritable bowel syndrome by increasing mainly Prevotella abundance. Scand J Gastroenterol. 54(12):1419–1425.
  • Yang T, Shu T, Liu G, Mei H, Zhu X, Huang X, Zhang L, Jiang Z. 2017. Quantitative profiling of 19 bile acids in rat plasma, liver, bile and different intestinal section contents to investigate bile acid homeostasis and the application of temporal variation of endogenous bile acids. J Steroid Biochem Mol Biol. 172:69–78.
  • Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, Nagler CR, Ismagilov RF, Mazmanian SK, Hsiao EY, et al. 2015. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 161(2):264–276.
  • Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, et al. 2013. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 499(7456):97–101.
  • Zhao L, Yang W, Chen Y, Huang F, Lu L, Lin C, Huang T, Ning Z, Zhai L, Zhong LL, et al. 2020. A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome. J Clin Invest. 130(1):438–450.
  • Zheng X, Huang F, Zhao A, Lei S, Zhang Y, Xie G, Chen T, Qu C, Rajani C, Dong B, et al. 2017. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice. BMC Biol. 15(1):120.
  • Zuo T, Kamm MA, Colombel JF, Ng SC. 2018. Urbanization and the gut microbiota in health and inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 15(7):440–452.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.